Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 658Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 6Janumet

02 10Januvia

03 1Sujanu

PharmaCompass

01

Brand Name : Janumet

Sitagliptin

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Janumet

arrow
2024 ACI Convention
Not Confirmed

Sitagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 1,971

2019 Revenue in Millions : 2,041

Growth (%) : -3

blank

02

Brand Name : Januvia

Sitagliptin

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Januvia

arrow
2024 ACI Convention
Not Confirmed

Sitagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 3,306

2019 Revenue in Millions : 3,482

Growth (%) : -5

blank

03

Brand Name : Janumet

Sitagliptin

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Janumet

arrow
2024 ACI Convention
Not Confirmed

Sitagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 1,964

2020 Revenue in Millions : 1,971

Growth (%) : 0

blank

04

Brand Name : Januvia

Sitagliptin Phosphate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Januvia

arrow
2024 ACI Convention
Not Confirmed

Sitagliptin Phosphate

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 3,324

2020 Revenue in Millions : 3,306

Growth (%) : 1

blank

05

Brand Name : Janumet

Sitagliptin

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Janumet

arrow
2024 ACI Convention
Not Confirmed

Sitagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 1,700

2021 Revenue in Millions : 1,964

Growth (%) : -13

blank

06

Brand Name : Sujanu

Sitagliptin

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Sujanu

arrow
2024 ACI Convention
Not Confirmed

Sitagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 94

2021 Revenue in Millions : 106

Growth (%) : -10

blank

07

Brand Name : Januvia

Sitagliptin Phosphate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Januvia

arrow
2024 ACI Convention
Not Confirmed

Sitagliptin Phosphate

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 2,813

2021 Revenue in Millions : 3,324

Growth (%) : -15

blank

08

Brand Name : Janumet

Sitagliptin

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Janumet

arrow
2024 ACI Convention
Not Confirmed

Sitagliptin

Main Therapeutic Indication : Diabetes

Currency : USD

2023 Revenue in Millions : 1,177

2022 Revenue in Millions : 1,700

Growth (%) : -31

blank

09

Brand Name : Januvia

Sitagliptin Phosphate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Januvia

arrow
2024 ACI Convention
Not Confirmed

Sitagliptin Phosphate

Main Therapeutic Indication : Diabetes

Currency : USD

2023 Revenue in Millions : 2,189

2022 Revenue in Millions : 2,813

Growth (%) : -22

blank

10

Brand Name : Januvia

Sitagliptin Phosphate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Januvia

arrow
2024 ACI Convention
Not Confirmed

Sitagliptin Phosphate

Main Therapeutic Indication : Diabetes

Currency : USD

2015 Revenue in Millions : 3,931

2014 Revenue in Millions : 3,863

Growth (%) : -2%

blank